IDH2 and acute myeloid leukemia: The combination of enasidenib and azacitidine appears to be effective in a phase 1b/2 study on newly diagnosed IDH2 mutated AML patients with ORR of 74% in the enasidenib + azacitidine group and 36% in the azacitidine monotherapy group.